Focused On-demand Library for Proton-coupled zinc antiporter SLC30A9, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Human embryonic lung protein; Solute carrier family 30 member 9; Zinc transporter 9

Alternative UPACC:

Q6PML9; Q4W5B6; Q7Z5I7; Q8TBB2; Q9Y6R2


The Proton-coupled zinc antiporter SLC30A9, mitochondrial, also known as Human embryonic lung protein, Solute carrier family 30 member 9, and Zinc transporter 9, plays a pivotal role in zinc homeostasis. It facilitates the export of zinc from the mitochondria, contributing to zinc mobilization, mitochondrial morphology, and overall health. Additionally, it acts as a secondary coactivator for nuclear receptors, enhancing transcriptional activation of Wnt-responsive genes.

Therapeutic significance:

Given its involvement in Birk-Landau-Perez syndrome, a condition marked by intellectual disability, muscle weakness, and nephropathy, understanding the role of Proton-coupled zinc antiporter SLC30A9 could open doors to potential therapeutic strategies. Its critical function in zinc homeostasis and mitochondrial health underscores its therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.